Compare Heron Therapeutics Inc (HRTX) vs Marqeta Inc (MQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Marqeta Inc — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Marqeta Inc trades at $17.29 (market cap $1.85B). The key difference: Marqeta Inc is far larger — about 20.2× Heron Therapeutics Inc's market cap, and Marqeta Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | MQ | |
|---|---|---|
Market Cap | $91.46M | $1.85B |
Sector | Health | Technology |
52-Week High | $1.96 | $27.32 |
52-Week Low | $0.39 | $15.04 |
Enterprise Value | $189.36M | $1.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Marqeta (MQ) trades at $17.45, down slightly by 0.23% today. The stock shows a bullish technical signal with strong moving average support, though RSI levels indicate mixed momentum. Fundamentally, the company reported revenue of $624.88M in 2025 (source: company filing 2025) but a net loss of $13.93M, with profitability metrics like net margin at 0.33% remaining thin. A recent 1-for-4 reverse stock split was effective July 1, 2026 (source: Business Wire 2026-06-29), aimed at boosting the share price amid restructuring efforts.
The outlook is cautiously optimistic with analyst consensus price target at $19.00 (source: MarketBeat 2026), implying potential upside, but high valuation ratios (P/E 436.88) and ongoing profitability challenges pose risks. Investor sentiment is mixed, balancing growth initiatives in Europe against competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
